Health care stocks fell late Friday afternoon with the NYSE Health Care Index declining 1.7% and the Health Care Select Sector SPDR Fund (XLV) dropping 1.8%.
The iShares Biotechnology ETF (IBB) slumped 4.7%.
In corporate news, Eyenovia (EYEN) shares plunged 69%. A phase 3 study evaluating the drug-device combination of low-dose atropine in the company's Optejet dispensing platform for pediatric progressive myopia didn't meet the primary endpoint. Eyenovia also is considering options including a business combination, reverse merger or asset sales.
Bluebird Bio (BLUE) shares sank 11% after BofA Securities downgraded the company's stock to neutral from buy.
Halozyme Therapeutics (HALO) offered to buy German drugmaker Evotec (EVO) for 2 billion euros ($2.11 billion). Halozyme shares tumbled 15%, and Evotec jumped past 6%.
CERo Therapeutics (CERO) shares surged 52%. The US Food and Drug Administration cleared the company's investigational new drug application for a phase 1 trial of its lead compound CER-1236 to treat acute myelogenous leukemia.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。